Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Ann & Robert H. Lurie Children's Hospital of Chicago has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to examiner MCKILLOP, JOHN CHARLES, the 1 distinct examiner for the portfolio. The work is concentrated in 1 distinct art unit. MCKILLOP, JOHN CHARLES is the busiest examiner with 1 pending office action. This indicates a focused prosecution profile with 1 pending action under the review of 1 distinct examiner.
The alignment of the 1 pending office action with a single examiner and 1 distinct art unit suggests a specific technical focus in the biotechnology sector. Practitioners should focus on the individual examination style of MCKILLOP, JOHN CHARLES to navigate the prosecution process effectively. Because the portfolio is limited to 1 distinct art unit, the technical arguments can be specialized for the pharmaceutical field. This arrangement allows for efficient communication and a consistent legal strategy. The absence of other pending matters or examiners means that the applicant's resources can be dedicated to resolving this 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
| GAO, ASHLEY HARTMAN | 1 | 56.7% | +38.2% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | WELLS, LAUREN QUINLAN | 56d overdue |
| 18839697 | SMALL MOLECULE DIRECTED URINARY BLADDER TISSUE REGENERATION | AULAKH, CHARANJIT | — |
| 18258440 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | GAO, ASHLEY HARTMAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | WELLS, LAUREN QUINLAN | 56d overdue |
| 18391200 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | GALSTER, SAMUEL LEONARD | — |
| 18258440 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| 1678 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839697 | SMALL MOLECULE DIRECTED URINARY BLADDER TISSUE REGENERATION | AULAKH, CHARANJIT | — | §102§103§112 | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18391200 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | GALSTER, SAMUEL LEONARD | 1693 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18258440 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | GAO, ASHLEY HARTMAN | 1678 | §101§103§112 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | WELLS, LAUREN QUINLAN | 1622 | §102§103§112 | Final Rejection | 56d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial